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Abstract
We previously reported that 43 (58%) of 75 head and neck squamous cell carcinoma (HNSCC)
tumors harbor increased epidermal growth factor receptor (EGFR) gene copy numbers as determined
by fluorescent in situ hybridization. In this study, an increased EGFR copy number was associated
with decreased progression-free survival and overall survival of HNSCC patients. However,
activated EGFR protein levels are difficult to quantify by immunohistochemistry and are subject to
dynamic regulation, specifically receptor downregulation on ligand binding. Therefore, we generated
an activated EGFR gene expression signature in an in vitro HaCaT keratinocyte model system to
further study genes involved in the EGFR signaling pathway in HNSCC. The results from this model
system have suggested that the activated EGFR signature might reflect the activated state of the
EGFR pathway in human HNSCC tumors and that it is associated with the increased EGFR gene
copy number by fluorescent in situ hybridization. Furthermore, the activated EGFR signature has
provided additional leads, because they are related to co-regulated molecular pathways and associated
gene products on activation of EGFR. These could be exploited to refine and optimize combination
therapies to be used in conjunction with available EGFR inhibitors in individual HNSCC patients.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) remains one of the most devastating cancers
in the United States. The sites affected by HNSCC (i.e., oral cavity, oropharynx, hypopharynx,
and larynx) are critical to the complex and vital functions of speech and swallowing. Despite
the advances of primary treatments, a large group of patients (30–40%) develop recurrence,
with very little improvement in overall survival (OS). Recently, the dearth of therapeutic
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options for HNSCC has motivated the search for targeted therapies for HNSCC. These efforts
have largely focused on the epidermal growth factor receptor (EGFR) because of epidemiologic
and mechanistic data implicating aberrant activation of this pathway in HNSCC. EGFR is a
type 1 membrane tyrosine kinase that plays important roles in the differentiation, proliferation,
and metastatic potential of a variety of human cancer cells, mostly those of epithelial origin
(1). Once the EGFR is activated, it triggers, in a cell type-specific manner, multiple signaling
events lead to phosphorylation of downstream effectors, including mitogen activated protein
kinase, Akt, and signal transducer and activator of transcription 3 (2,3). The EGFR is highly
expressed in >95% of HNSCCs, and increased protein expression of EGFR and its ligand,
transforming growth factor-α (TGF-α), by immunohistochemical staining is associated with a
poor prognosis in HNSCC patients (4,5).
We previously reported that 43 (58%) of 75 HNSCC tumors harbor an increased EGFR gene
copy number as determined by fluorescent in situ hybridization (FISH) and that an increased
EGFR copy number is associated with decreased progression-free survival and overall survival
for HNSCC patients (6). Patients with FISH-positive tumors had a median time to progression
of 18 months and to death of 20 months and those with FISH-negative tumors had a median
time to progression of 25 months and to death of 29 months. This difference was statistically
significant for progression-free survival (p <0.05, log–rank test) and overall survival (p <0.01,
log–rank test), although we were limited by the heterogeneity of the patient population and
treatments received. FISH status did not correlate with the EGFR gene or protein expression
levels assessed either by quantitative polymerase chain reaction (PCR) or
immunohistochemical staining using the DAKO EGFR PharmDx kit. This discrepancy was
presumably due to the dilution effects of the DNA and RNA levels in quantitative PCR, reverse
transcriptase (RT)-PCR, and microarray assays in which entire tumors are analyzed compared
with the FISH analysis in which only 50–100 tumor cells within the area of FISH positivity
are counted. Furthermore, the EGFR protein levels are difficult to quantify by
immunohistochemical staining and are subject to dynamic regulation, specifically receptor
downregulation on ligand binding. Therefore, we generated an EGFR signature using a HaCaT
cell model system that reflected the overall gene expression pattern of the activated state of
the EGFR pathway and correlated this EGFR signature with previously determined EGFR gene
copy number data in HNSCC tumors.
METHODS AND MATERIALS
Cell preparation
The HaCaT cells overexpressing EGFR (HaCaT-EGFR) were maintained in culture media
(W489) as described previously (7,8). After incubation in serum-free media, the cells were
stimulated with TGF-α 10 ng/mL for 4 h and harvested for total RNA isolation in parallel with
unstimulated control cells.
RNA preparation and DNA microarray analyses
Gene expression was determined from three HaCaT-EGFR cell cultures to increase our
confidence in the statistical analyses. Total RNA was isolated using the Qiagen RNeasy Mini
kit (Qiagen, Valencia, CA) and amplified and labeled using the NuGEN WT-Ovation RNA
Amplification kit (NuGEN, San Carlos, CA), according to the manufacturer's
recommendations. Next, 15 μg of biotin-labeled aRNA was fragmented and hybridized on to
the Affymetrix Human Genome U133 plus 2.0 GeneChip. After hybridization, the GeneChip
was washed, stained with strepavidin/phycoerythrin conjugate and biotinylated antibody, and
scanned according to the manufacturer's recommendations. The raw microarray data were
normalized and uploaded into the VMSR database for analysis.
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All arrays were analyzed using the Robust Multichip Analysis approach. Differentially
expressed genes between EGF stimulation and no stimulation in the HaCaT-EGFR cells were
selected by statistical criteria of greater than twofold changes and p <0.05 by Student's t test.
Determination of co-regulated genes/pathways with activation of EGFR on stimulation of
EGF
The data were further mined using Ingenuity Pathways Analysis (IPA). The selected
differential gene log ratios were submitted to the IPA application. The IPA mapped these genes
to their corresponding gene objects in the Ingenuity Pathways Knowledge Base. A p value was
generated for each mapped network by comparing the number of differential genes that
participated in a given network relative to the total number of occurrences of those genes in
all the possible network permutations for all the objects in the Ingenuity Pathways Knowledge
Base. The network score was assessed for statistical significance, and the generated pathway
maps were examined for biologic correlations.
Validation of array data using RT-PCR
The mRNA expression levels of EGFR and the EGFR ligands (EGF, TGF-α [TGFA], heparin-
binding EGF-like growth factor [HB-EGF], and neuregulin 1 [NRG1]) were confirmed by
RTPCR in HaCaT cells, first with and without EGFR overexpression (HaCaT-vector vs.
HaCaT-EGFR) and, second, with and without EGF stimulation. The RT-PCR for each gene
was performed in triplicate with control genes, including GUSB, 18S, and PPIA. The RT-PCR
data were analyzed using the 2−ΔΔCt method, as described previously (9).
RESULTS
Examination of the EGFR mRNA levels using RT-PCR in the HaCaT-vector and HaCaT-
EGFR cells with and without EGF stimulation after serum stimulation has shown that HaCaT-
EGFR cells express greater levels of EGFR mRNA compared with HaCaT-vector and that
ligand stimulation up-regulates the expression of the receptor itself (Fig. 1A). The activated
EGFR signature determined by comparing the gene expression profile of the EGF-stimulated
vs. EGF-unstimulated HaCaT-EGFR cells contained 234 probe sets or 207 unique genes.
Examination of these genes in the context of biologic pathways using IPA revealed two key
signaling pathways with increased expression levels on EGF stimulation. The two pathways
included upregulation of Myc and vascular endothelial growth factor as their central genes in
the network, as well as upregulation of EGFR ligands, NRG1, heparin-binding EGF-like
growth factor, and TGFA. The differential expression levels of these ligands were confirmed
using RT-PCR (Fig. 1B). Furthermore, downregulation of CDKN1B and CEPB4 was
consistently observed in EGF-stimulated HaCaT-EGFR cells.
In previous work, we identified high expression of Myc and vascular endothelial growth factor
in HNSCC patients with a poor prognosis (10,11). TGFA is an important EGFR ligand, and
high expression of TGFA is also associated with a poor prognosis in HNSCC (5). NRG1 or
heregulin is a ligand for Her3 that can heterodimerize with other Her family receptors and
provide an escape mechanism to EGFR inhibitors (12,13). These key genes in the center of
each pathway are important because manipulation of the central genes can regulate many genes
linked within the network. These types of pathway analyses can provide information on novel
targets and mechanisms of drug resistance and sensitivity. For instance, if a specific pathway
is consistently upregulated in patients who were resistant to cetuximab or gefitinib, a
combination regimen targeting that particular pathway could overcome the resistance. For
example, anti-angiogenic agents to block vascular endothelial growth factor are already
available in clinical settings and can be combined with EGFR inhibitors.
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To determine the relevance of the activated EGFR signature as observed in HaCaT-EGFR cells
to human HNSCC, the signature generated from HaCaT-EGFR cells was queried in a human
data set generated from 44 HNSCC tumors, 3 normal tonsillar epithelia, and 3 normal mucosal
epithelia adjacent to tumors and clustered to visualize the signature (Fig. 2). The tumors in
Cluster 2 had a positive median correlation with the activated EGFR signature, indicating that
the signature in the human data set resembled the EGF-stimulated cells. The tumors in Cluster
1 had a negative median correlation with the signature, resembling the unstimulated cells.
Therefore, Cluster 2 with the positive correlation was determined to have the activated EGFR
pathway. Of the 44 HNSCC tumors in Fig. 2, 33 had an increased EGFR gene copy number,
as determined by FISH. Cluster 2 had more samples with FISH positivity than did Cluster 1
(p <0.0001, pair-wise t test comparison).
DISCUSSION
These preliminary data suggest that the activated EGFR signature generated from HaCaT cells
in vitro might reflect the activated state of the EGFR pathway in human HNSCC and that an
increased EGFR gene copy number leads to increased EGFR activity. Therefore, the observed
poor prognosis in patients with EGFR FISH positivity is most likely related to activation of
the EGFR pathway. Furthermore, the activated EGFR signature provides additional leads,
because they relate to co-regulated molecular pathways and associated gene products on
activation of EGFR. However, the genes suggested as the activated EGFR signature are also
frequently induced by other stimulants and are dependent on the in vitro experimental
conditions, indicating that the diagnosis and/or prognosis using this signature could be
misleading in general clinical applications. In addition, the HNSCC tumor data were generated
from a small retrospective study of a heterogeneous patient population. Therefore, these
preliminary data must be validated with a larger study of homogeneously treated patients with
EGFR inhibitors before being exploited for refining and optimizing combination therapies in
conjunction with available EGFR inhibitors in individual patients.
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mRNA expression levels in HaCaT cells with empty vector without epidermal growth factor
(EGF) stimulation (vector control) and with EGF stimulation (vector stimulated), and HaCaT
cells with EGF receptor (EGFR) overexpression without EGF stimulation (EGFR control) and
with EGF stimulation (EGFR stimulated) of (A) EGFR and (B) EGFR ligands, EGF, heparin-
binding EGF-like growth factor (HBEGF), neuregulin 1 (NRG1), and transforming growth
factor-TGF-α (TGFA).
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Hierarchical clustering of 50 frozen samples (44 head-and-neck squamous cell carcinoma
[HNSCC] tumors, 3 normal mucosal epithelia adjacent to tumors, and 3 normal tonsillar
epithelia) using activated epidermal growth factor receptor (EGFR) signature generated from
EGFR overexpressing HaCaT cell with and without EGF stimulation. For 33 of 44 HNSCC
tumors, EGFR fluorescent in situ hybridization (FISH) data were available. FISH data labeled
as follows: HP = high polysomy; GA = gene amplification; LP = low polysomy; LT = low
trisomy; and NL = normal disomy. Suffix “-AN” indicates mucosal epithelia adjacent to
tumors.
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